Your browser doesn't support javascript.
loading
Immune recovery in HIV-1 infected patients with sustained viral suppression under long-term antiretroviral therapy in Ethiopia.
Wolday, Dawit; Legesse, Dorsisa; Kebede, Yazezew; Siraj, Dawd S; McBride, Joseph A; Striker, Robert.
Afiliação
  • Wolday D; Mekelle University College of Health Sciences, Mekelle, Ethiopia.
  • Legesse D; Hayat General Hospital, Addis Ababa, Ethiopia.
  • Kebede Y; Mekelle University College of Health Sciences, Mekelle, Ethiopia.
  • Siraj DS; Division of Infectious Diseases, Department of Medicine, University of Wisconsin, Madison, Wisconsin, United States of America.
  • McBride JA; Division of Infectious Diseases, Department of Medicine, University of Wisconsin, Madison, Wisconsin, United States of America.
  • Striker R; Division of Infectious Diseases, Department of Medicine, University of Wisconsin, Madison, Wisconsin, United States of America.
PLoS One ; 15(10): e0240880, 2020.
Article em En | MEDLINE | ID: mdl-33091053
BACKGROUND: There is very little data on long-term immune recovery responses in patients on suppressive antiretroviral therapy (ART) in the setting of sub-Saharan Africa (SSA). Thus, we sought to determine CD4+ T-cell, CD8+ T-cell and CD4/CD8 ratio responses in a cohort of HIV infected individuals on sustained suppressive ART followed up for more than a decade. METHODS: The cohort comprised adult patients who started ART between 2001 and 2007 and followed for up to 14 years. Trends in median CD4+ T-cells, CD8+ T-cells and CD4/CD8 ratio were reviewed retrospectively. Poisson regression models were used to identify factors associated with achieving normalized T-cell biomarkers. Kaplan-Meier curves were used to estimate the probability of attaining normalized counts while on suppressive ART. RESULTS: A total of 227 patients with a median duration of follow-up on ART of 12 (IQR: 10.5-13.0) years were included. CD4 cell count increased from baseline median of 138 cells (IQR: 70-202) to 555 cells (IQR: 417-830). CD4 cell increased continuously up until 5 years, after which it plateaued up until 14 years of follow up. Only 69.6% normalized their CD4 cell count within a median of 6.5 (IQR: 3.0-10.5) years. In addition, only 15.9% of the cohort were able to achieve the median reference CD4+ T-cell threshold count in Ethiopians (≈760 cells/µL). CD8+ T-cell counts increased initially until year 1, after which continuous decrease was ascertained. CD4/CD8 ratio trend revealed continuous increase throughout the course of ART, and increased from a median baseline of 0.14 (IQR: 0.09-0.22) to a median of 0.70 (IQR: 0.42-0.95). However, only 12.3% normalized their ratio (≥ 1.0) after a median of 11.5 years. In addition, only 8.8% of the cohort were able to achieve the median reference ratio of healthy Ethiopians. CONCLUSION: Determination of both CD4+ and CD8+ T-cells, along with CD4/CD8 ratio is highly relevant in long-term follow-up of patients to assess immune recovery. Monitoring ratio levels may serve as a better biomarker risk for disease progression among patients on long-term ART. In addition, the findings emphasize the relevance of initiation of ART at the early stage of HIV-1 infection.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T CD4-Positivos / Infecções por HIV / Linfócitos T CD8-Positivos / Fármacos Anti-HIV / Terapia Antirretroviral de Alta Atividade Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País como assunto: Africa Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T CD4-Positivos / Infecções por HIV / Linfócitos T CD8-Positivos / Fármacos Anti-HIV / Terapia Antirretroviral de Alta Atividade Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País como assunto: Africa Idioma: En Ano de publicação: 2020 Tipo de documento: Article